Using Period Analysis to Timely Assess and Predict 5-Year Relative Survival for Liver Cancer Patients From Taizhou, Eastern China

Frontiers in Oncology

Yongran Cheng¹  Liangyou Wang¹  Luyao Zhang¹  Fang Han²  Xiyi Jiang³  Youqing Wang³  Runhua Li⁴  Yuhua Zhang⁵  Tianhui Chen⁶  Jianguang Ji⁷  Jinfei Chen⁷ 

[1] Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China;Department of Cancer Epidemiology and Prevention, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory of Cancer Prevention, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China;Department of Cancer Prevention/Zhejiang Cancer Institute, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital);Department of Hepatobiliary and Pancreatic Surgery, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital);Department of Non-Communicable Chronic Disease Control and Prevention, Taizhou Center for Disease Control and Prevention, Taizhou, China;Department of Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China;School of Public Health, Hangzhou Medical College, Hangzhou, China;

关键词: 5-year relative survival;    liver cancer;    period analysis;    cancer registry;    eastern China;   

DOI  :  10.3389/fonc.2022.920094

来源: DOAJ

【 摘 要 】

IntroductionWhile timely assessment of long-term survival for patients with liver cancer is essential for the evaluation of early detection and screening programs of liver cancer, those data are extremely scarce in China. We aimed to timely and accurately assess long-term survival for liver cancer patients in eastern China.MethodsPatients diagnosed with liver cancer during 2004–2018 from four cancer registries with high-quality data from Taizhou, eastern China, were included. The period analysis was used to calculate the 5-year relative survival (RS) for overall and the stratification by sex, age at diagnosis, and region. The projected 5-year RS of liver cancer patients during 2019–2023 was also assessed using a model-based period analysis.ResultsThe overall 5-year RS for patients with liver cancer during 2014–2018 reached 32.4%, being 29.3% for men and 36.1% for women. The 5-year RS declined along with aging, decreasing from 38.2% for age <45 years to 18.8% for age >74 years, while the 5-year RS for urban area was higher compared to rural area (36.8% vs. 29.3%). The projected overall 5-year RS of liver cancer patients could reach 41.4% during the upcoming period 2019–2023.ConclusionsWe provided, for first time in China using the period analysis, the most up-to-date 5-year RS for patients with liver cancer from Taizhou, eastern China, and also found that the 5-year RS for liver cancer patients have improved greatly during 2004–2018, which has important implications for the timely evaluation of early detection and screening programs for patients with liver cancer in eastern China.

【 授权许可】

Unknown